


# Listing of Claims:

This listing of claims replaces all prior versions, and listings, of claims in the captioned application.


1. (Previously Presented) A compound having the formula



an *N*-oxide, salt, stereoisomeric form, racemic mixture, prodrug, or ester thereof, wherein

$R_1$  and  $R_8$  are, each independently, hydrogen,  $C_{1-6}$ alkyl,  $C_{2-6}$ alkenyl, aryl $C_{1-6}$ alkyl,  $C_{3-7}$ cycloalkyl,  $C_{3-7}$ cycloalkyl $C_{1-6}$ alkyl, aryl, Het<sup>1</sup>, Het<sup>1</sup> $C_{1-6}$ alkyl, Het<sup>2</sup>, or Het<sup>2</sup> $C_{1-6}$ alkyl;

$R_1$  may also be a radical of formula



wherein

$R_9$ ,  $R_{10a}$  and  $R_{10b}$  are, each independently, hydrogen,  $C_{1-4}$ alkyloxycarbonyl, carboxyl, aminocarbonyl, mono- or di( $C_{1-4}$ alkyl)aminocarbonyl,  $C_{3-7}$ cycloalkyl,  $C_{2-6}$ alkenyl,  $C_{2-6}$ alkynyl or  $C_{1-6}$ alkyl optionally substituted with aryl, Het<sup>1</sup>, Het<sup>2</sup>,  $C_{3-7}$ cycloalkyl,  $C_{1-4}$ alkyloxycarbonyl, carboxyl, aminocarbonyl, mono- or di( $C_{1-4}$ alkyl)aminocarbonyl, aminosulfonyl,  $C_{1-4}$ alkylS(O)<sub>i</sub>, hydroxy, cyano, halogen or amino optionally mono- or disubstituted where the substituents are each independently selected from  $C_{1-6}$ alkyl, aryl, aryl $C_{1-4}$ alkyl,  $C_{3-7}$ cycloalkyl,  $C_{3-7}$ cycloalkyl $C_{1-4}$ alkyl, Het<sup>1</sup>, Het<sup>2</sup>, Het<sup>1</sup> $C_{1-4}$ alkyl and Het<sup>2</sup> $C_{1-4}$ alkyl; wherein  $R_9$ ,  $R_{10a}$  and the carbon atoms to which they are attached may also form a  $C_{3-7}$ cycloalkyl radical; when L is -O- $C_{1-6}$ alkanediyl-C(=O)- or -NR<sub>8</sub>- $C_{1-6}$ alkanediyl-C(=O)-, then  $R_9$  may also be oxo;

$R_{11a}$  is hydrogen,  $C_{2-6}$ alkenyl,  $C_{2-6}$ alkynyl,  $C_{3-7}$ cycloalkyl, aryl, aminocarbonyl optionally mono- or disubstituted, amino $C_{1-4}$ alkylcarbonyloxy optionally

mono- or disubstituted, C<sub>1-4</sub>alkyloxycarbonyl, aryloxycarbonyl, Het<sup>1</sup>oxycarbonyl, Het<sup>2</sup>oxycarbonyl, aryloxycarbonylC<sub>1-4</sub>alkyl, arylC<sub>1-4</sub>alkyloxycarbonyl, C<sub>1-4</sub>alkylcarbonyl, C<sub>3-7</sub>cycloalkylcarbonyl, C<sub>3-7</sub>cycloalkylC<sub>1-4</sub>alkyloxycarbonyl, C<sub>3-7</sub>cycloalkylcarbonyloxy, carboxylC<sub>1-4</sub>alkylcarbonyloxy, C<sub>1-4</sub>alkylcarbonyloxy, arylC<sub>1-4</sub>alkylcarbonyloxy, arylcarbonyloxy, aryloxycarbonyloxy, Het<sup>1</sup>carbonyl, Het<sup>1</sup>carbonyloxy, Het<sup>1</sup>C<sub>1-4</sub>alkyloxycarbonyl, Het<sup>2</sup>carbonyloxy, Het<sup>2</sup>C<sub>1-4</sub>alkylcarbonyloxy, Het<sup>2</sup>C<sub>1-4</sub>alkyloxycarbonyloxy or C<sub>1-6</sub>alkyl optionally substituted with aryl, aryloxy, Het<sup>2</sup> or hydroxy; wherein the substituents on the amino groups are each independently selected from C<sub>1-6</sub>alkyl, aryl, arylC<sub>1-4</sub>alkyl, C<sub>3-7</sub>cycloalkyl, C<sub>3-7</sub>cycloalkylC<sub>1-4</sub>alkyl, Het<sup>1</sup>, Het<sup>2</sup>, Het<sup>1</sup>C<sub>1-4</sub>alkyl and Het<sup>2</sup>C<sub>1-4</sub>alkyl;

R<sub>11b</sub> is hydrogen, C<sub>3-7</sub>cycloalkyl, C<sub>2-6</sub>alkenyl, C<sub>2-6</sub>alkynyl, aryl, Het<sup>1</sup>, Het<sup>2</sup> or C<sub>1-6</sub>alkyl optionally substituted with halogen, hydroxy, C<sub>1-4</sub>alkylS(=O)<sub>t</sub>, aryl, C<sub>3-7</sub>cycloalkyl, Het<sup>1</sup>, Het<sup>2</sup>, amino optionally mono- or disubstituted where the substituents are each independently selected from C<sub>1-4</sub>alkyl, aryl, arylC<sub>1-4</sub>alkyl, C<sub>3-7</sub>cycloalkyl, C<sub>3-7</sub>cycloalkylC<sub>1-4</sub>alkyl, Het<sup>1</sup>, Het<sup>2</sup>, Het<sup>1</sup>C<sub>1-4</sub>alkyl and Het<sup>2</sup>C<sub>1-4</sub>alkyl;

wherein R<sub>11b</sub> may be linked to the remainder of the molecule via a sulfonyl group;

t is, each independently, zero, 1 or 2;

R<sub>2</sub> is hydrogen or C<sub>1-6</sub>alkyl;

L is -C(=O)-, -O-C(=O)-, -NR<sub>8</sub>-C(=O)-, -O-C<sub>1-6</sub>alkanediyl-C(=O)-, -NR<sub>8</sub>-C<sub>1-6</sub>alkanediyl-C(=O)-, -S(=O)<sub>2</sub>-, -O-S(=O)<sub>2</sub>-, -NR<sub>8</sub>-S(=O)<sub>2</sub>, wherein either the C(=O) group or the S(=O)<sub>2</sub> group is attached to the NR<sub>2</sub> moiety; and wherein each independently the C<sub>1-6</sub>alkanediyl moiety may be optionally substituted with hydroxy, aryl, Het<sup>1</sup> or Het<sup>2</sup>;

R<sub>3</sub> is C<sub>1-6</sub>alkyl, aryl, C<sub>3-7</sub>cycloalkyl, C<sub>3-7</sub>cycloalkylC<sub>1-4</sub>alkyl, or arylC<sub>1-4</sub>alkyl;

R<sub>4</sub> is hydrogen, C<sub>1-4</sub>alkyloxycarbonyl, carboxyl, aminocarbonyl, mono- or di(C<sub>1-4</sub>alkyl)aminocarbonyl, C<sub>3-7</sub>cycloalkyl, C<sub>2-6</sub>alkenyl, C<sub>2-6</sub>alkynyl or C<sub>1-6</sub>alkyl optionally substituted with one or more substituents each independently selected from aryl, Het<sup>1</sup>, Het<sup>2</sup>, C<sub>3-7</sub>cycloalkyl, C<sub>1-4</sub>alkyloxycarbonyl, carboxyl, aminocarbonyl, mono- or di(C<sub>1-4</sub>alkyl)aminocarbonyl, aminosulfonyl, mono- or di(C<sub>1-4</sub>alkyl)aminosulfonyl, C<sub>1-4</sub>alkylS(=O)<sub>t</sub>, hydroxy, cyano, halogen or amino optionally mono- or disubstituted where the substituents are each independently selected from C<sub>1-4</sub>alkyl, aryl, arylC<sub>1-4</sub>alkyl, C<sub>3-7</sub>cycloalkyl, C<sub>3-7</sub>cycloalkylC<sub>1-4</sub>alkyl, Het<sup>1</sup>, Het<sup>2</sup>, Het<sup>1</sup>C<sub>1-4</sub>alkyl and Het<sup>2</sup>C<sub>1-4</sub>alkyl;



<sub>4</sub>alkylcarbonyl, C<sub>1-4</sub>alkylcarbonyloxy, C<sub>1-4</sub>alkyloxycarbonyl, C<sub>1-4</sub>alkylcarbonyloxyC<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkyloxycarbonylC<sub>1-4</sub>alkyl, aryl, C<sub>3-7</sub>cycloalkyl, Het<sup>1</sup> and Het<sup>2</sup>; and  
R<sub>6</sub> is hydrogen.

5. (Currently Amended) A compound selected from the group consisting of:

(1-Benzyl-2-hydroxy-3-{isobutyl-[2-oxo-3-(1H-pyrrol-2-ylmethylene)-2,3-dihydro-1H-indole-5-sulfonyl]-amino}-propyl)-carbamic acid hexahydro-furo[2,3-b]furan-3-yl ester ,

(1-Benzyl-2-hydroxy-3-{isobutyl-[3-(5-methyl-furan-2-ylmethylene)-2-oxo-2,3-dihydro-1H-indole-5-sulfonyl]-amino}-propyl)-carbamic acid hexahydro-furo[2,3-b]furan-3-yl ester ,

(1-Benzyl-2-hydroxy-3-{isobutyl-[3-(5-methyl-thiophen-2-ylmethylene)-2-oxo-2,3-dihydro-1H-indole-5-sulfonyl]-amino}-propyl)-carbamic acid hexahydro-furo[2,3-b]furan-3-yl ester ,

(1-Benzyl-2-hydroxy-3-{isobutyl-[3-(1-methyl-1H-pyrrol-2-ylmethylene)-2-oxo-2,3-dihydro-1H-indole-5-sulfonyl]-amino}-propyl)-carbamic acid hexahydro-furo[2,3-b]furan-3-yl ester ,

(1-Benzyl-3-{[3-(2-ethyl-butylidene)-2-oxo-2,3-dihydro-1H-indole-5-sulfonyl]-isobutyl-amino}-2-hydroxy-propyl)-carbamic acid hexahydro-furo[2,3-b]furan-3-yl ester ,

{1-Benzyl-2-hydroxy-3-[isobutyl-(3-isobutylidene-2-oxo-2,3-dihydro-1H-indole-5-sulfonyl)-amino]-propyl}-carbamic acid hexahydro-furo[2,3-b]furan-3-yl ester ,

{1-Benzyl-3-[(3-furan-2-ylmethylene)-2-oxo-2,3-dihydro-1H-indole-5-sulfonyl]-isobutyl-amino]-2-hydroxy-propyl}-carbamic acid hexahydro-furo[2,3-b]furan-3-yl ester ,

(1-Benzyl-2-hydroxy-3-{isobutyl-[3-(4-methoxy-benzylidene)-2-oxo-2,3-dihydro-1H-indole-5-sulfonyl]-amino}-propyl)-carbamic acid hexahydro-furo[2,3-b]furan-3-yl ester ,

(1-Benzyl-2-hydroxy-3-{isobutyl-[2-oxo-3-(4-pyridin-2-yl-benzylidene)-2,3-dihydro-1H-indole-5-sulfonyl]-amino}-propyl)-carbamic acid hexahydro-furo[2,3-b]furan-3-yl ester ,

(1-Benzyl-2-hydroxy-3-{[3-(4-hydroxy-3,5-dimethyl-benzylidene)-2-oxo-2,3-dihydro-1H-indole-5-sulfonyl]-isobutyl-amino}-propyl)-carbamic acid hexahydro-furo[2,3-b]furan-3-yl ester ,

(1-Benzyl-3-{[3-(4-dimethylamino-benzylidene)-2-oxo-2,3-dihydro-1H-indole-5-sulfonyl]-isobutyl-amino}-2-hydroxy-propyl)-carbamic acid hexahydro-furo[2,3-b]furan-3-yl ester ,

(1-Benzyl-2-hydroxy-3-{[3-(1H-indol-2-ylmethylene)-2-oxo-2,3-dihydro-1H-indole-5-sulfonyl]-isobutyl-amino}-propyl)-carbamic acid hexahydro-furo[2,3-b]furan-3-yl ester ,

Acetic acid 5-(5-{[3-(hexahydro-furo[2,3-b]furan-3-yloxycarbonylamino)-2-hydroxy-4-phenyl-butyl]-isobutyl-sulfamoyl}-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-furan-2-ylmethyl ester ,

{1-Benzyl-3-[(3-benzylidene-2-oxo-2,3-dihydro-1H-indole-5-sulfonyl)-isobutyl-amino]-2-hydroxy-propyl}-carbamic acid hexahydro-furo[2,3-b]furan-3-yl ester ,

(1-Benzyl-3-{[3-(4-diethylamino-3-hydroxy-benzylidene)-2-oxo-2,3-dihydro-1H-indole-5-sulfonyl]-isobutyl-amino}-2-hydroxy-propyl)-carbamic acid hexahydro-furo[2,3-b]furan-3-yl ester ,

(1-Benzyl-2-hydroxy-3-{[3-(2-hydroxy-benzylidene)-2-oxo-2,3-dihydro-1H-indole-5-sulfonyl]-isobutyl-amino}-propyl)-carbamic acid hexahydro-furo[2,3-b]furan-3-yl ester ,

(1-Benzyl-2-hydroxy-3-{isobutyl-[3-(2-methoxy-benzylidene)-2-oxo-2,3-dihydro-1H-indole-5-sulfonyl]-amino}-propyl)-carbamic acid hexahydro-furo[2,3-b]furan-3-yl ester ,

(1-Benzyl-2-hydroxy-3-{[3-(4-hydroxy-3-methoxy-benzylidene)-2-oxo-2,3-dihydro-1H-indole-5-sulfonyl]-isobutyl-amino}-propyl)-carbamic acid hexahydro-furo[2,3-b]furan-3-yl ester ,

(1-Benzyl-3-{isobutyl-[3-(5-methylfuran-2-ylmethylene)-2-oxo-2,3-dihydro-1H-indole-5-sulfonyl]-amino}-2-phosphonooxy-propyl)-carbamic acid hexahydro-furo[2,3-b]furan-3-yl ester ,

4-(5-{[3-(Hexahydro-furo[2,3-b]furan-3-yloxycarbonylamino)-2-hydroxy-4-phenyl-butyl]-isobutyl-sulfamoyl}-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-benzoic acid , and

~~a-N-oxides, or a salts, and thereof, or a stereoisomeric forms thereof.~~

6. (Previously Presented) A pharmaceutical composition, comprising an effective amount of at least one compound as claimed in claim 1, and a pharmaceutically tolerable excipient.
7. (Cancelled)

8. (Currently Amended) A method of treating infection or disease associated with multi-drug resistant human immunodeficiency virus (HIV) retrovirus infection in a mammal, comprising administering an effective amount of at least one compound according to claim 1 to said mammal.
9. (Cancelled)
10. (Cancelled)
11. (Cancelled)
12. (Previously Presented) A pharmaceutical composition, comprising an effective amount of at least one compound as claimed in claim 2 and a pharmaceutically tolerable excipient.
13. (Cancelled)
14. (Currently Amended) A method of treating infection or disease associated with multi-drug resistant human immunodeficiency virus (HIV)retrovirus infection in a mammal, comprising administering an effective amount of at least one compound according to claim 2 to said mammal.
15. (Cancelled)
16. (Previously Presented) A pharmaceutical composition, comprising an effective amount of at least one compound as claimed in claim 5 and a pharmaceutically tolerable excipient.
17. (Cancelled)
18. (Currently Amended) A method of treating infection or disease associated with multi-drug resistant human immunodeficiency virus (HIV)retrovirus infection in a mammal, comprising administering an effective amount of at least one compound according to claim 5 to said mammal.



19. (Cancelled)
20. (Previously Presented) A pharmaceutical composition, comprising an effective amount of at least one compound as claimed in claim 1 and a pharmaceutically tolerable excipient.
21. (Previously Presented) A pharmaceutical composition, comprising an effective amount of at least one compound as claimed in claim 3 and a pharmaceutically tolerable excipient.
22. (Previously Presented) A pharmaceutical composition, comprising an effective amount of at least one compound as claimed in claim 4 and a pharmaceutically tolerable excipient.
23. (Previously Presented) A pharmaceutical composition, comprising an effective amount of at least one compound as claimed in claim 6 and a pharmaceutically tolerable excipient.